<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381249</url>
  </required_header>
  <id_info>
    <org_study_id>CRFSJ 0057</org_study_id>
    <nct_id>NCT02381249</nct_id>
  </id_info>
  <brief_title>The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery</brief_title>
  <official_title>The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. James's Hospital, Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dublin, Trinity College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GÃ¶teborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. James's Hospital, Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improvements to treatment strategies for patients with cancers of the upper gastrointestinal
      tract have produced a large population of people who remain free from cancer recurrence in
      the long term following treatment.

      Surgery is the cornerstone of treatment for patients with these cancers, but while surgical
      removal of the tumour may offer the best chance of cure, these are major operations
      associated with specific long term complications. Weight loss and poor nutrition are common
      problems among patients who attain long-term cancer remission and cure after surgery. The
      mechanisms underlying these problems are not well understood and therefore treatment options
      are limited.

      Our research has demonstrated increased levels of chemical messengers (gut hormones) released
      from the gastrointestinal tract after meals in patients who have previously undergone this
      type of surgery. These chemical messengers play a role in controlling appetite and interest
      in food, and increased levels after surgery may reduce interest in eating. Understanding the
      role of gut hormones in the control of appetite may allow us to use certain medications to
      block gut hormones and hence increase appetite, allowing patients to eat more and regain
      weight, preventing nutritional problems after surgery.

      In this study, the investigators aim to determine whether exaggerated gut hormone secretion
      causes reduced appetite and interest in food after surgery. The information gained from this
      study may help us to develop treatments for patients with weight loss and nutritional
      problems after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progressive ratio task breakpoint for a sweet-fat reward</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of rewards consumed</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective symptom score</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Sigstad score</measure>
    <time_frame>3 hours</time_frame>
    <description>Both categorical and continuous</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Stomach Neoplasms</condition>
  <condition>Weight Loss</condition>
  <condition>Malnutrition</condition>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Duodenal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Esophagectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-blind single dose octreotide-placebo crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-blind single dose octreotide-placebo crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unoperated healthy control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double-blind single dose octreotide-placebo crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreaticoduodenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-blind single dose octreotide-placebo crossover</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen</description>
    <arm_group_label>Esophagectomy</arm_group_label>
    <arm_group_label>Gastrectomy</arm_group_label>
    <arm_group_label>Unoperated healthy control</arm_group_label>
    <arm_group_label>Pancreaticoduodenectomy</arm_group_label>
    <other_name>Sandostatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen</description>
    <arm_group_label>Esophagectomy</arm_group_label>
    <arm_group_label>Gastrectomy</arm_group_label>
    <arm_group_label>Unoperated healthy control</arm_group_label>
    <arm_group_label>Pancreaticoduodenectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Surgical procedure: Two-stage, three-stage or transhiatal esophagectomy with gastric
             conduit reconstruction and pyloroplasty, total gastrectomy with Roux-en-Y
             reconstruction, pancreaticoduodenectomy, or matched healthy unoperated control
             subjects

          2. Disease-free at least one year post-resection

        Exclusion criteria:

          1. Pregnancy, breastfeeding

          2. Significant and persistent chemoradiotherapy and/or surgical complication

          3. Other previous upper gastrointestinal surgery

          4. Unwell or unable to eat

          5. Other disease or medications which may affect satiety gut hormone responses

          6. Active and significant psychiatric illness including substance misuse

          7. Cognitive or communication issues or any factors affecting capacity to consent to
             participation

          8. History of significant food allergy, certain dietary restrictions

          9. Confirmed or suspected residual or recurrent disease after surgery, second primary
             malignancy

         10. Requiring adjuvant chemotherapy

         11. Contraindication to octreotide administration

         12. History of eating disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John V Reynolds, MCh, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, St. James's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wellcome Trust-Health Research Board Clinical Research Facility, St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrosurgical Laboratory, Sahlgrenska Academy, University of Gothenburg</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.sjhcrf.ie</url>
    <description>Wellcome Trust-HRB Clinical Research Facility</description>
  </link>
  <link>
    <url>http://www.ucd.ie/conway/</url>
    <description>Conway Institute of Biomolecular and Biomedical Research</description>
  </link>
  <link>
    <url>https://medicine.tcd.ie/surgery/</url>
    <description>Department of Surgery, Trinity College Dublin and St. James's Hospital</description>
  </link>
  <reference>
    <citation>Miras AD, Jackson RN, Jackson SN, Goldstone AP, Olbers T, Hackenberg T, Spector AC, le Roux CW. Gastric bypass surgery for obesity decreases the reward value of a sweet-fat stimulus as assessed in a progressive ratio task. Am J Clin Nutr. 2012 Sep;96(3):467-73. doi: 10.3945/ajcn.112.036921. Epub 2012 Jul 25.</citation>
    <PMID>22836034</PMID>
  </reference>
  <reference>
    <citation>HODOS W. Progressive ratio as a measure of reward strength. Science. 1961 Sep 29;134(3483):943-4.</citation>
    <PMID>13714876</PMID>
  </reference>
  <reference>
    <citation>Miholic J, Orskov C, Holst JJ, Kotzerke J, Pichlmayr R. Postprandial release of glucagon-like peptide-1, pancreatic glucagon, and insulin after esophageal resection. Digestion. 1993;54(2):73-8.</citation>
    <PMID>8319842</PMID>
  </reference>
  <reference>
    <citation>Haverkort EB, Binnekade JM, Busch OR, van Berge Henegouwen MI, de Haan RJ, Gouma DJ. Presence and persistence of nutrition-related symptoms during the first year following esophagectomy with gastric tube reconstruction in clinically disease-free patients. World J Surg. 2010 Dec;34(12):2844-52. doi: 10.1007/s00268-010-0786-8.</citation>
    <PMID>20842361</PMID>
  </reference>
  <reference>
    <citation>Koizumi M, Hosoya Y, Dezaki K, Yada T, Hosoda H, Kangawa K, Nagai H, Lefor AT, Sata N, Yasuda Y. Postoperative weight loss does not resolve after esophagectomy despite normal serum ghrelin levels. Ann Thorac Surg. 2011 Apr;91(4):1032-7. doi: 10.1016/j.athoracsur.2010.11.072.</citation>
    <PMID>21440118</PMID>
  </reference>
  <reference>
    <citation>le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006 Jan;243(1):108-14.</citation>
    <PMID>16371744</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>February 9, 2016</last_update_submitted>
  <last_update_submitted_qc>February 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. James's Hospital, Ireland</investigator_affiliation>
    <investigator_full_name>Dr Jessie A Elliott</investigator_full_name>
    <investigator_title>Surgical Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Esophagectomy</keyword>
  <keyword>Gastrectomy</keyword>
  <keyword>Octreotide</keyword>
  <keyword>Somatostatin</keyword>
  <keyword>Appetite</keyword>
  <keyword>Hunger</keyword>
  <keyword>Glucagon-Like Peptide 1</keyword>
  <keyword>Peptide YY</keyword>
  <keyword>Reinforcement</keyword>
  <keyword>Reward</keyword>
  <keyword>Psychological Phenomena and Processes</keyword>
  <keyword>Gastrointestinal Agents</keyword>
  <keyword>Nutritional Status</keyword>
  <keyword>Pancreaticoduodenectomy</keyword>
  <keyword>Whipple Procedure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Duodenal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

